Regulatory T cells (Tregs) are critical for the peripheral maintenance of the autoreactive T cells in autoimmune disorders such as type 1 diabetes (T1D). Pharmacological inhibition of Janus tyrosine kinase 3 (JAK3) has been proposed as a basis for new treatment modalities against autoimmunity and allogeneic responses. Targeting JAK3 with an inhibitor has previously been shown to exhibit protective action against the development of T1D in non-obese diabetic (NOD) mice. As the mechanism of such preventative action has been unknown, we hypothesized that JAK3 inhibition induces generation of Tregs. Here, we show that the JAK3 inhibitor 4-(49-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) suppresses proliferation of short-term cultured NOD CD4
INTRODUCTION

Regulatory CD4
1 T cells (Tregs) have been shown to actively suppress the function of conventional T cells, and play a crucial role in controlling undesired immune responses to self-antigens. Their protective role has been described in a non-obese diabetic (NOD) mouse model of autoimmune type 1 diabetes (T1D), [1] [2] [3] [4] as well as in human T1D. 5 There are two major types of Tregs, 'natural' Tregs (nTregs), 6 and 'induced or adaptive' Tregs (iTregs). 7, 8 The extracellular expression of a high-affinity IL-2 receptor a-chain (CD25) and the nuclear expression of FoxP3 in CD4
1 T cells are considered as the nTreg markers. There is no particular molecule that marks iTreg population. However, iTregs can be divided into at least two different groups based on the type of cytokines that they secrete: IL-10-secreting iTregs and transforming growth factor (TGF)-b-secreting Th3-type Tregs. 4, 7, 8 Janus tyrosine kinase 3 (JAK3), a member of JAK family, is cytoplasmic protein tyrosine kinase which plays a pivotal role in the initiation of cytokine-triggered signaling events by activating the cytoplasmic latent forms of signal transducer and activator of transcription (STAT) factor 5 via tyrosine phosphorylation on the specific tyrosine residues.
9 JAK3 specifically associates with the cc subunit of the IL-2 receptor, and is activated by the cytokines IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 that use the cc receptor. 10, 11 It is known that JAK3 is abundantly expressed in lymphoid cells and plays an important role in normal lymphocyte proliferation, differentiation and function, as evidenced by qualitative and quantitative deficiencies in the T-cell compartment of the immune system of JAK3-deficient mice 12, 13 and the development of severe combined immunodeficiency in JAK3-deficient patients.
14 Therefore, targeting JAK3 has been proposed as a new modality for immunosuppression of T cell-mediated pathologies, such as transplant rejection and autoimmunity. [15] [16] [17] [18] The structure-based design of specific inhibitors of JAK3 has been reported previously. 19 It has been shown that the lead compound, 4-(49-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) suppresses mitogen-and antigen-induced responses in vitro. 20, 21 In vivo treatment with WHI-P131 attenuated the severity of T celldependent graft-versus-host disease post murine allogeneic bone marrow transplantation, 20, 22, 23 and prevented rejection of mouse allogeneic islet cell transplants. 24 Furthermore, WHI-P131 treatment prevented development of T1D in NOD mice. 25 When cytokine profile was analyzed in splenocytes of WHI-P131-treated NOD mice, a clear skewing from pathogenic Th1-towards protective Th2-type immune response was not found. Thus, the efforts to characterize the mechanisms of protective action of JAK3 inhibitors in T1D development of NOD mice provided inconclusive results in the context of Th1/Th2 paradigm. 25 Recent studies have indicated that some conventional immunosuppressive drugs exhibit beneficial effects on Treg induction and function, whereas others may be detrimental. 26 For example, rapamycin can induce generation of mouse, 27 as well as human 28,29 CD4
1 CD25 1
FoxP3
1 Tregs under specific in vitro condition. Moreover, rapamycin has been found to expand Tregs in vitro, allowing this rare cell type to become available for clinical applications. [27] [28] [29] In contrast, in vitro and in vivo studies with cyclosporine A showed inhibition of FoxP3 expression, 30 compromised thymic generation, and reduction in peripheral Tregs. 31 The action of both cyclosporine A and rapamycin is associated with cytokine IL-2. Differential effects of those drugs on Tregs may be explained by differences in signal transduction pathways. Whereas cyclosporin inhibits phosphatase calcineurin, thereby suppressing the IL-2 production, 32 rapamycin inhibits IL-2 signaling by binding the mammalian target of rapamycin, with a consequent suppression of a cell cycle. 33, 34 The JAK3 inhibitors inhibit IL-2 signaling as well, but through the JAK3/STAT5 pathway. 10, 11 While JAK3 signaling is fairly well understood, the influence of JAK3 inhibitors on the induction of Tregs in vitro and in vivo has not been studied yet.
Considering the beneficial effects of the JAK3 inhibitor WHI-P131 in the prevention of T1D, and its unclear mechanism of protection, along with its potential influence on the generation of Tregs, we hypothesized that the induction of Tregs is the mechanism of protective WHI-P131 action. Therefore, the aim of this study was to evaluate the effect of JAK3 inhibition by WHI-P131 on the murine Tregs in vitro and in vivo.
MATERIALS AND METHODS
Mice NOD mice, originally bought from The Jackson Laboratory (Bar Harbor, ME, USA), were bred in our Animal Care Facility at St. Cloud State University (SCSU). Mice were fed ad libitum with rodent diet Harlan Teklad 18% Global Protein Diet 2018. We have shown that hyperglycemia can occur in our colony of NOD females as early as 8 weeks of age. 35 Therefore, all mice used in our experiments were 5-to 7-week-old prediabetic females that showed no signs of hyperglycemia. All procedures that included manipulation of live animals (euthanasia, detection of glycemia and drug injection regimens) were approved by the SCSU Institutional Animal Care and Use Committee.
Cell isolation, stimulation and culturing Spleens were removed from NOD females and a single-cell suspension was prepared. 36 Lymphocytes were isolated from pancreata and pancreatic lymph nodes, as described previously. 24, 36 CD4 1 cells were isolated by magnetic separation using anti-CD4-coated magnetic microbeads and MS and LS columns (Myltenyi Biotec; Auburn, CA, USA).
Isolated CD4
1 T cells were cultured in a concentration of 1-3310 6 / ml in RPMI 1640 (supplemented with 10% fetal calf serum, Hyclone; Logan, UT, USA) and stimulated with plate-bound anti-CD3 (10 mg/ml) and anti-CD28 (2 mg/ml) antibodies (BD Biosciences; San Jose, CA, USA). JAK3 kinase inhibitor WHI-P131 (Calbiochem; San Diego, CA, USA) was added to the cell cultures in the concentrations of 6, 3 and 1.5 mg/ml (18, 9 and 4.5 mM, respectively). A control drug, rapamycin (Sigma; St. Louis, MO, USA), known to induce generation of CD4
FoxP3
1 Tregs in vitro, 27 was added in the concentrations of 1000, 100 and 10 nM. Briefly, CD4
1 T cells were stimulated and cultured with addition of drugs for 7 days. The cells were then washed, recounted and restimulated with addition of drugs. Three rounds of stimulation of 7 days each were performed, as described previously. 27, 37 IL-2 (2 mg/ml; BD Biosciences) was added starting from the second round of cell stimulation. 27, 37 At the end of the third week of culturing, the cells were washed, stimulated without the drug addition and analyzed appropriately.
Detection of cell proliferation Proliferation was measured by using Cell Proliferation ELISA (BrdU) Immunoassay kit from Roche (Indianapolis, IN, USA). Isolated CD4 1 T cells were stimulated as described above and cultured for 72 h with addition of WHI-P131. Cells were then labeled with BrdU according to manufacturer's instruction, and the optical density was determined within 30 min using a microplate reader at 450 nm.
Detection of cell viability during the long-term culturing During the 3 weeks of culturing, at the end of each week, CD4
1 T cells were collected, washed, counted and cell viability determined by trypan blue exclusion test. Based on the total number of viable cells, they were again put in the culture and restimulated by anti-CD3, anti-CD28 and IL-2 with addition of WHI-P131 or rapamycin.
Detection of apoptosis Apoptosis was measured in CD4
1 T cells cultured for 72 h (shortterm) by using Cell Death Detection ELISA kit (Roche) according to the manufacturer's instruction. This kit provides relative quantification of histone-complexed DNA fragments of the cells that have undergone apoptosis. The optical density was determined using a microplate reader at 450 nm. Apoptosis was also measured by flow cytometry in long-term (3 weeks) vs. short-term (48 h) cultured CD4 
Immunophenotyping of cells by flow cytometry
Monoclonal antibodies against mouse CD3 and CD8 markers were purchased from BD Biosciences. Mouse Regulatory T Cell Staining kit (eBiosciences; San Diego, CA, USA), containing anti-CD4-FITC, -CD25-APC and -FoxP3-PE antibodies, was used for a characterization of CD4 1 T cells either in vitro cultured for 3 weeks with addition of WHI-P131 or rapamycin, or ex vivo isolated from NOD mice treated in vivo by these drugs. Cells were stained according to the manufacturer's instruction and analyzed by BD FACSCalibur (BD Biosciences).
Detection of cytokines ELISA tests (Quantikine mouse IL-2, IL-4, IL-10, interferon (IFN)-c and human TGF-b1; R&D Systems; Minneapolis, MN, USA) were used for quantifying cytokine concentrations in CD4 1 cell supernatants obtained post long-term culturing with addition of WHI-P131 and rapamycin in vitro. The same cytokines were detected in the supernatants of the isolated CD4 1 T cells obtained post in vivo treatment of NOD mice with WHI-P131 and rapamycin. The supernatants were collected and stored at 280 uC until the measurement. The optical density was determined using a microplate reader at 450 nm.
In vivo treatment of mice by WHI-P131 and rapamycin In the first experiment, 4-to 6-week-old prediabetic NOD females (n57) were injected intraperitoneally with 75 mg/kg of WHI-P131
(dissolved in 5% dimethyl sulfoxide in phosphate-buffered saline), daily (twice/day) for 10 days. Control mice (n56) received vehicle control. After the treatment, mice were killed, and CD4 1 T cells were magnetically isolated (as described above), and stimulated with anti-CD3 plus anti-CD28 antibodies for 48 h. Cell supernatants were collected for detection of cytokines (IL-10, IL-4, IL-2, IFN-c and TGFb1). In the second experiment, 4-to 6-week-old NOD females (n56) were treated with 1 mg/kg/day of rapamycin (dissolved in phosphatebuffered saline), while the controls received vehicle control for a duration of 10 days. Afterwards, CD4
1 T cells were isolated, stimulated and cultured for 48 h. The supernatants were collected and cytokines were analyzed by ELISA.
RESULTS
WHI-P131 suppresses the proliferation of short-term cultured isolated CD4
1 T cells
It has been previously shown that the JAK3 inhibitor WHI-P131 exhibits a potent dose-dependent suppression of proliferative responses of non-diabetic C57BL/6 and NOD mouse T cells induced by both mitogens 20, 25 and an autoantigen, GAD65. 25 However, these studies did not confirm the effects of the JAK3 inhibitor on a particular subpopulation of T cells, such as CD4 1 T cells. To define the effect of WHI-P131 on isolated CD4
1 T-cell population, CD4 1 cells were isolated by positive magnetic beads separation from the spleens of NOD mice. Isolated cells were activated with plate-bound anti-CD3 and soluble anti-CD28 Aby with or without the addition of different concentrations (1.5, 3 and 6 mg/ml) of WHI-P131, and proliferation was measured by BrdU ELISA post 72 h of culturing. The chosen concentrations of WHI-P131 were selected based on our previously obtained results showing that doses of 5-100 mg/ml of WHI-P131 completely suppressed proliferation of a heterogeneous population of T cells. 20 Here, we show that the additions of 1.5, 3 and 6 mg/ml of WHI-P131 induced a dose-dependent, statistically significant reduction in proliferation of CD4 1 T cells compared to vehicle-exposed controls ( Figure 1a ).
WHI-P131 induces apoptotic cell death in short-term cultured isolated CD4
It has been demonstrated that WHI-P131 induces apoptotic cell death of tumor cell lines in vitro.
19,21 Therefore, we asked whether an apoptotic cell death is the mechanism of WHI-P131-induced suppression of CD4 1 cell proliferation. Cells were activated by the combination of anti-CD3 and anti-CD28 antibodies, and cultured with the additions of 1.5, 3 and 6 mg/ml of WHI-P131 for 72 h. Apoptotic cell death was detected by ELISA. Figure 1b shows that the addition of WHI-P131 causes a dose-dependent increase in apoptotic cell death in cultured CD4 1 T cells. Therefore, an induction of cell death is the mechanism of suppressed proliferation of CD4 1 cells cultured for a short period of time with the addition of WHI-P131.
WHI-P131 allows survival of isolated CD4
1 T cells during longterm culturing Rapamycin selectively expands murine CD4 1 CD25 1 FoxP3 1 nTregs 27 during long-term culturing consisting of three rounds of stimulations of naive CD4 1 T cells. In contrast, the proapoptotic effect of rapamycin has been shown in the short-term cultures of both murine 27 and human CD4
1 T cells. 29 To define the effects of long-term exposure of T cells on the JAK3 inhibitor, naive CD4 1 T cells, isolated from NOD spleens, were activated with a plate-bound anti-CD3 and soluble anti-CD28 antibodies for 3 consecutive weeks in the presence or absence of different concentrations of WHI-P131. The viability was evaluated by trypan blue exclusion test post each week of culturing. Rapamycin (10, 100 and 1000 nM) was used as a control drug-treatment. After the first week of culturing, there was a significant reduction in the percentages of viable cells observed in all of the WHI-P131-treated groups compared to the control cells ( Figure 2 ). The highest concentration of the drug (6 mg/ml) induced significantly more pronounced reduction in cell viability (17.1%61.4%) compared to the one observed in the cells exposed to 1.5 mg/ml of the drug (42.3%61.7%). Rapamycin, as well, affected the viability of cells post first week of culturing ( Figure 2) . However, the dose-dependent response was not observed. After the second round of stimulation, there was a trend of reduced viability, which did not reach a significant difference in T-cell cultures exposed to 6, 3 and 1.5 mg/ml of WHI-P131 compared to control cultures ( Figure 2 ). In contrast, the numbers of viable cells obtained by the end of the third week of activation with the additions of 6, 3 and 1.5 mg/ ml of WHI-P131 were comparable to the control cells ( Figure 2 ). The addition of rapamycin (all three concentrations) during the second, as well as the third week of stimulation, did not reduce the viability of cultured cells compared to controls ( Figure 2 ).
As shown previously and here (Figure 1b ), WHI-P131 induces apoptotic cell death in the primary cells 20 and cell lines 19 cultured for a short period of time. Our cell viability data, observed in cultures exposed to WHI-P131 after the first and second week of stimulation, are in agreement with apoptosis induction. In contrast, an increased viability of drug-exposed isolated CD4
1 T cells, observed post longterm culturing, suggests potential resistance of surviving cells to proapoptotic effect of WHI-P131, or the outgrowth of a pre-existing res- Figure 3 shows that addition of all concentrations of WHI-P131 during the 48-h culture period significantly increased the percentage of doublepositive (Annexin V 1 /PI 1 ) apoptotic cells compared to controls. Addition of WHI-P131 in concentrations of 6 and 3 mg/ml significantly elevated the percentages of apoptotic cells to 49%67% and 52%64%, respectively, compared to 30%62% in 1.5 mg/ml-treated group. In contrast, a significant reduction in the cell death percentages was observed in the cultures exposed to WHI-P131 during the 3 weeks vs. 48 h of culturing ( Figure 3 ). The next experiment was set up in order to test whether all surviving long-term cultured T cells have been initially resistant to JAK3 inhibition. The CD4 1 T cells were stimulated during the 3 weeks with anti-CD3 plus anti-CD28 antibodies without the exposure to WHI-P131. After the three rounds of culturing, cells were exposed to WHI-P131 for 48 h. While 8.3%60.7% of control untreated cells were apoptotic, 47.2%611.3%, 41.0%68.7% and 25.1%65.9% became apoptotic post exposure to 6, 3 and 1.5 mg/ml of WHI-P131, respectively, confirming that long-term culturing per se does not generate T cells resistant to JAK3 inhibition. Similar results were obtained by the addition of rapamycin in shortvs. long-term cultures of CD4 1 cells. Thus, rapamycin (all tested concentrations) induced a significant increase in the percentage of cell death in short-term cultures of CD4 1 T cells compared to controls (Figure 3 ). In contrast, flow cytometric analysis of Annexin V/PI double-positive cells, performed at the end of the third week, revealed a significant reduction in the percentages of apoptotic cells in the cultures exposed to 1000, 100 and 10 nM of rapamycin, respectively, compared to the percentages of apoptotic cells observed post short-term exposure to the same concentrations of the drug. In conclusion, these data are in line with the viability data obtained post first (short-term) and third week of culturing (long-term) with the addition of WHI-P131. In addition, presented results suggest that a long-term exposure to the JAK3 inhibitor allows a particular fraction of cultured CD4
1 T cells to become more resistant to proapoptotic action of this drug, or the outgrowth of a preexisting resistant population.
WHI-P131 does not promote growth of CD4
1 CD25 1 FoxP3 1 cells during long-term culturing After the three rounds of stimulation with anti-CD3 and anti-CD28 antibodies, CD4
1 T cells were rested with the addition of IL-2 and restimulated with the same antibodies overnight. The next day, a flow cytometric analysis was performed in order to quantify the expression of surface markers CD4 and CD25, and intracellular marker FoxP3. The majority of control cells (82%62%), generated over the 3 weeks of culturing, were CD4
1 CD25 1 double-positive cells. (Figure 4a and c) . The WHI-P131 addition in doses of 1.5, 3 and 6 mg/ml, prominently reduced the populations of CD25
1 FoxP3 1 cells in a dose-dependent manner to 2.0%60.3%, 1.2%60.2% and 0.3%60.2%, respectively (Figure 4a and d) . In contrast, addition of 1 T cells with addition of WHI-P131. Apoptotic cell death was detected using Annexin-V/PI double staining of CD4 1 T cells stimulated as described in Figure 2 , and cultured with addition of WHI-P131 in the concentrations of 1.5, 3 and 6 mg/ml (P1.5, P3 and P6, respectively) or rapamycin in the concentrations of 10, 100 and 1000 nM (R10, R100 and R1000, respectively) for 48 h (striped bars) or 3 weeks (dotted bars). Data are presented as an average percentage of double-positive (Annexin-V 1 /PI 1 ) cells6s.e.m. of five samples/group. Statistical analysis performed by Student's t-test. *P,0.05 compared to control; **P,0.05 compared to the same drug concentration at different culturing periods; ***P,0.05 compared to the optimal rapamycin drug concentration (R100). WHI-P131, 4-(49-hydroxyphenyl)-amino-6,7-dimethoxyquinazolin.
Figure 2 Viability of CD4
1 T cells, presented as a percentage of the initial cell number, exposed to WHI-P131 during long-term (3 weeks) culture period. Isolated CD4 1 T cells were stimulated and cultured (three rounds of stimulation with anti-CD3 and anti-CD28 antibodies, 7 days each) with addition of WHI-P131 in the concentrations of 1.5, 3 and 6 mg/ml (P1.5, P3 and P6, respectively), or rapamycin in the concentrations of 10, 100 and 1000 nM (R10, R100 and R1000, respectively). Viability was measured using trypan blue exclusion test after the first (clear bars), second (striped bars) and third (dotted bars) week of culturing. Data presented as average percentage6s.e.m. of five experiments with 4-6 samples/ group. Statistical analysis performed by Student's t-test. *P,0.05 compared to control. WHI-P131, 4-(49-hydroxyphenyl)-amino-6,7-dimethoxyquinazolin.
JAK3 inhibition induces TGF
rapamycin in the concentrations of 10, 100 and 1000 nM significantly increased the percentages of CD25 (Figure 4a and e) . Similarly, the trend of changes in CD4 1
FoxP3
1 cell population exposed to WHI-P131 and rapamycin followed those observed in CD25 1
1 cells. As previously described, 27 the exposure of CD4 1 cells to 100 nM rapamycin most prominently increased the percentage of FoxP3 1 cells to 19.2%64.4% compared to 4.9%61.1% in a control group (Figure 4b, f and h) . In contrast to the rapamycin, addition of WHI-P131 did not induce FoxP3 expression in long-term cultures of CD4 1 T cells: only 1.7%60.2%, 1.5%60.5% and 0.4%60.3% of CD4 1
1 cells were detected post exposure to 1.5, 3 and 6 mg/ml of WHI-P131, respectively (Figure 4b and g ). 37 An elevated secretion of IL-10 has been observed previously in a heterogeneous, concanavalin A-activated splenic T-cell population, isolated from NOD mice post in vivo treatment with WHI-P131. 25 Therefore, we hypothesized that WHI-P131, while not inducing FoxP3 1 nTregs, can allow generation of IL-10-secreting Tr-1 cells during long-term culturing. Results shown on Figure 5a do not confirm our hypothesis. The secretion of IL-10 in the long-term cultures of stimulated CD4 1 T cells was significantly decreased if the cells were treated with 6 and 3 mg/ml of WHI-P131 (Figure 5a) . The same supernatants were tested for the amount of IL-2, IL-4, IFN-c and TGF-b. While IL-2 secretion was not detected at all (data not shown), the IFN-c (Figure 5c ) and IL-4 levels ( Figure 5b ) were significantly reduced in the supernatants of cells exposed to WHI-P131. These data suggest that the WHI-P131 addition to cultures of CD4 1 cells does not induce generation of Tr-1 or Th1-/Th2-type T 
1 T cells. CD4 1 T cells were stimulated, cultured for 3 weeks with addition of WHI-P131 in the concentrations of 1.5, 3 and 6 mg/ml (P1.5, P3 and P6, respectively) or rapamycin in the concentrations of 10, 100 and 1000 nM (R10, R100 and R1000, respectively) and stained for flow cytometric analysis with anti-CD4-FITC, anti-FoxP3-PE and anti-CD25-APC antibodies. Data are presented as average6s.e.m. of six samples/group. Statistical analysis performed by Student's t-test. *P,0.05 compared to control. The representative dot plots of: CD25 1 cells exposed to WHI-P131 in the concentrations of 3 and 1.5 mg/ml (Figure 5d ), suggesting a Th3-type Treg phenotype induction during the long-term culturing under described in vitro conditions. The highest concentration of 6 mg/ml of WHI-P131 did not increase TGF-b secretion, as this drug concentration induced significantly higher level of apoptotic cell death after the long-term culturing, compared to control (Figure 3 
In vivo treatment with WHI-P131 does not induce FoxP3 expression but elevates TGF-b secretion in CD4 1 T cells
The next set of experiments was performed in order to define the effects of in vivo treatment with WHI-P131 on nTregs (FoxP3 expression), as well as cytokine profiles of ex vivo-extracted CD4 1 T cells. NOD females (n57) were treated with 75 mg/kg/day of WHI-P131, a dose expected to be effective in vivo. 25 A control group of mice received a vehicle control treatment (n56). Mice were killed post 10 days of treatment, spleens were removed and viability of splenocytes was determined by trypan blue exclusion test. It was found that WHI-P131 treatment in vivo does not affect viability of splenocytes, as 96%65% were alive, compared to 89%63% in controls. These results confirm previously published data regarding the non-toxic effects of this JAK3 inhibitor. 25, 38 The splenocytes obtained from WHI-P131-treated and control mice were analyzed for CD3, CD8, CD4 and FoxP3 expression by flow cytometry. There were no differences in the percentages of the CD3 WHI-P131 treatment does not affect the frequency and total numbers of nTregs in the secondary lymphatic organ such as spleen. However, it should be considered that its effect could be observed in lymph nodes located in a vicinity of the pancreas. Therefore, an additional set of experiments was performed in order to answer whether in vivo treatment with WHI-P131 (75 mg/kg/day during a 10-day period) affects Treg population in the pancreatic lymph nodes (PLNs) of NOD females. Figure 6c shows that there were no differences observed in the percentages of CD3 1 , CD4 1 , CD8 1 and CD4 1 FoxP3 1 T cells in the PLNs of drug-treated and control mice. The average of the absolute cell numbers obtained from the PLNs of six mice administered with WHI-P131was higher (0.94310 6 60.23310 6 ), but not significantly different, from the average PLN cell number of the six controls (0.68310 6 60.11310 6 ). Similar to the spleen results, the absolute number of PLN CD4 1 T cells was significantly higher in mice treated with WHI-P131 than in controls, while the numbers of all other studied T-cell sub-populations, including the CD4 1 FoxP3 1 cells, remained unaffected (Figure 6d) .
The following three experiments were performed, with PLN and pancreatic infiltrate (PL) cells being pooled in each experiment, from the seven control and seven drug-treated mice. Results showed again 1 T cells stimulated and cultured for 3 weeks with addition of WHI-P131 in the concentrations of 1.5, 3 and 6 mg/ml (P1.5, P3 and P6, respectively) or rapamycin in the concentrations of 10, 100 and 1000 nM (R10, R100 and R1000, respectively). Data are presented as average (pg/ml)6s.e.m. of 5-6 samples/group. Statistical analysis performed by Student's t-test. *P,0.05 compared to control. IFN, interferon; TGF, transforming growth factor; WHI-P131, 4-(49-hydroxyphenyl)-amino-6,7-dimethoxyquinazolin.
JAK3 inhibition induces TGF-b secretion in CD4
1 T cells M Cetkovic-Cvrlje et al 355 that WHI-P131 treatment did not affect the frequency of CD4 1 FoxP3 1 PL cells, compared to controls (data not shown). In contrast, cytokine analysis showed that the PLs, isolated from the WHI-P131-treated mice, produced significantly (P,0.05) higher amount of TGF-b (18106203 pg/ml) compared to controls (7326125 pg/ml), along with decreased amount of IFN-c (18606410 pg/ml vs. 41306502 pg/ml) and IL-2 (12006540 pg/ml vs. 32906478 pg/ml). Whereas a trend of increased production of IL-10 and lower IL-4 was observed in mice treated with WHI-P131, significant changes were not obtained (data not shown). Overall, the results observed in the PLNs and PLs agree with those obtained in the spleens, pointing to the increased number of CD4 1 FoxP3 2 T cells and elevated production of TGF-b in NOD mice post in vivo exposure to the JAK3 kinase inhibitor. In addition, in vivo data are in agreement with those obtained in vitro, suggesting the WHI-P131-induced generation of CD4 1 FoxP3 2 T cells that secrete TGF-b.
The next in vivo experiment included rapamycin administration (1 mg/kg/day) of NOD females for 10 days (six treated and six control mice), in order to compare the cytokine levels and immunophenotyping results obtained by WHI-P131 and rapamycin treatment. Flow cytometric analysis showed that there was a significant increase (P,0.05) in CD4
1 CD25 1 cells in rapamycin-treated (6.3%60.3%) vs. control mice (5.0%60.2%). FoxP3 expression was elevated as well. Thus, 5.9%60.2% of cells were CD4
1 FoxP3 1 in rapamycin-treated, compared to 4.6%60.4% in control mice (P,0.05). Figure 8 shows that rapamycin treatment significantly increased IL-10 ( Figure 8a ) and 
DISCUSSION
Here, we reintroduced the question about the mechanism of protective antidiabetogenic WHI-P131 action in NOD mice, asking whether targeting JAK3 with this inhibitor would induce generation of Tregs. First, the effects of the JAK3 inhibition were studied in vitro. We showed that WHI-P131 acts directly on CD4 1 T cells, suppressing the proliferation by inducing apoptotic cell death during short-term culturing of these cells. This observation is important, as previous studies explored the antiproliferative and apoptotic effects of WHI-P131 in the context of lymphoblastic and myeloblastic leukemia cells, 19, 21 and a heterogeneous population of murine splenic cells, 15, 20, 24 not CD4 1 T cells in particular. In contrast to short-term culturing, long-term exposure of CD4 1 cells to WHI-P131 provided different experimental data. Thus, the viability of cells, significantly reduced during the first week of exposure to WHI-P131, reached the control values post 3 weeks of culturing. In line with viability data, the flow cytometric analysis revealed a significant reduction in apoptoic cell death of CD4 1 cells exposed to WHI-P131 over the period of 3 weeks, compared to short-term exposure. Similar results were obtained in rapamycin-treated groups, which are in accordance with pathway in these cells. 33, 39 Thus, engagement of the IL-2 receptor on Tregs resulted in the activation of the JAK/STAT signaling pathway, but failed to activate downstream targets of the PI3K signaling pathway, such as AKT or p70-S6 kinase. 33 Furthermore, it has been shown that IL-2-mediated upregulation of FoxP3 in purified CD4
1 CD25 1 T cells involves the binding of STAT3/5 proteins to a highly conserved STAT binding site located in the first intron of the FoxP3 gene. 39 Our data clearly show that the JAK3 inhibitor WHI-P131 inhibits differentiation of CD4 1 T cells towards the nTreg CD4 1 CD25 1 FoxP3 1 phenotype, confirming the essential role of the JAK3/STAT5 signaling pathway for the induction of CD4 1 FoxP3 1 T cells in vitro. Furthermore, these results are in line with studies performed in JAK3-deficient mice. 40 Mayack and Berg 40 showed that activated JAK3 2/2 CD4 1 T cells, while able to suppress the proliferation of effector cells, do not express FoxP3.
Here, we provide experimental evidence that CD4 1 T cells generated by in vitro exposure to WHI-P131 secrete an elevated level of TGF-b. An absence of IL-2 secretion, accompanied by the decreased levels of IFN-c, IL-4 and IL-10 suggests that these cells are neither conventional Th1-/Th2-nor IL-10-secreting Tr-1-type T cells. In line with our data, it has been described that CD4
1 cells isolated from 
JAK3 inhibition induces TGF-b secretion in CD4
1 T cells M Cetkovic-Cvrlje et al 357 JAK3-deficient mice secrete an elevated level of TGF-b. 40 However, increased IL-10 secretion was found as well. Interestingly, decreased IFN-c secretion, like in our case, was observed in phytohemagglutinin-stimulated blood leukocytes of kidney transplant patients treated by the JAK3 inhibitor CP-690,550. 41 Unfortunately, the TGF-b secretion in these patients was not measured. Numerous studies have identified roles for TGF-b in preventing T1D in NOD mice by blocking the cytotoxic effects of diabetogenic effector lymphocytes. 42 Recent studies have demonstrated that regulatory T cells protect from T1D in the context of TGF-b. 43, 44 Furthermore, the protective treatments of NOD mice attributed their beneficial actions to upregulation of TGF-b-producing Tregs as well. 45, 46 These TGF-b-producing Tregs, called by some as Th3-type Tregs, are believed to develop in the presence of TGF-b. 8 While some reports have defined them as FoxP3 2 adaptive Tregs, 7 a substantial number of studies have demonstrated that Th3 cells express FoxP3. 47, 48 However, it should be noted that research in the Th3 field has focused on mucosal tissue in the intestine, as these cells are found to be important in intestinal diseases and in maintaining tolerance to intestinal antigens. 47, 48 It has been shown that WHI-P131 in the doses of 50 and 100 mg/kg was effective in the prevention of T1D in NOD mice. 15, 25 Moreover, there were no drug-related toxic lesions found during histopathological examinations in any of the organs of mice treated with 100 mg/kg/ day. 25 In accordance with these studies, we chose a dosage of 75 mg/ kg of WHI-P131 for our in vivo experiments. As previously described, 25 we again observed that WHI-P131 treatment does not change the frequency of CD3 1 , CD4
1 and CD8 1 splenocytes. The same results were observed in the PLNs, the secondary lymphoid organs directly involved in immunopathogenesis of the autoimmune attack. However, an analysis of the absolute numbers of these T-cell sub-populations pointed out towards the elevated numbers of CD4 1 cells in the spleens, as well as in the PLNs of mice treated with WHI-P131, suggesting that JAK3 inhibitor increases the CD4 1 T-cell numbers in vivo. Furthermore, the frequency, as well as the absolute numbers of CD4 1
FoxP3
1 T cells, in the spleens and PLNs of NOD mice was not affected by WHI-P131 treatment. A recent study investigated the effect of JAK3 kinase inhibitor CP-690,550 on Treg number and function in human kidney transplant recipients enrolled in a phase 1 dose-escalation safety trial. 41 A marked reduction in the CD4 1
CD25
bright population was observed in patients treated with CP-690,550 over the 2 weeks, compared to baseline value. However, this study lacked a placebo control group and analyzed a very small sample size. 41 Moreover, as those patients had already been immunosuppressed from the beginning of the study, more clinical research should be done before the final conclusion can be 
FoxP3
1 T cells, confirming the previously published results. 45 TGF-b was the only cytokine significantly increased in the spleens, PLNs, as well as in the pancreata of NOD mice in vivo treated by WHI-P131. All other studied cytokines were either significantly decreased, such as IL-2, IFN-c and IL-4, or not significantly different than the controls, such as IL-10. The cytokine profiles, obtained from stimulated CD4
1 cells isolated from spleens of rapamycin-treated mice, while in accordance with elevated IL-10 and unchanged TGF-b levels described by Battaglia et al., 45 were different from those observed post WHI-P131 treatment. Thus, we clearly show here a disparate action of rapamycin vs. WHI-P131 on the murine Tregs in vitro and in vivo.
Conventional immunosuppressive drugs have various direct and indirect effects on Tregs. 26, 49 The majority of reports have reflected on the effects of these drugs on the CD4 1
1 Tregs. 26, 49 Rapamycin's beneficial effects on the induction of FoxP3 1 Tregs in vitro 27-29 and in vivo 45, 50 have been well documented and discussed throughout this paper. It has been shown that corticosteroids induce FoxP3 expression in vitro, 51 and expand nTreg population post shortterm administration in vivo. 52 Mycophenolate mofetil neither altered the expression of FoxP3, nor affected Treg function in vitro. 53 In contrast, calcineurin inhibitors, such as cyclosporine A and tacrolimus, exhibited negative effects on CD4
1 FoxP3 1 Tregs both in vitro and in vivo.
30,31 Here, we show that the JAK3 inhibitor does suppress generation of CD4
1 FoxP3 1 cells in vitro, while not depleting them in vivo. To our knowledge, this is the first report exploring a direct in vitro and in vivo effect of JAK3 inhibition on the murine nTregs. Further studies would need to address the functional capability of these CD4 1
1 cells post-treatment with WHI-P131. Interestingly, our results are in line with studies performed with IL-2 receptor blocking antibodies. It has been shown that these antibodies, which directly interfere with receptor signaling by inhibiting IL-2 binding and subsequent phosphorylation of the IL-2 receptor b-and c-chains, inhibit FOXP3 mRNA induction, 30 and expansion of CD4
1
CD25
1 cells in vitro, 54 while not depleting the peripheral Treg numbers after the in vivo treatment. 55 In summary, we have shown that JAK3 inhibition by WHI-P131 promotes TGF-b secretion by CD4 1 T cells in vitro and in vivo. Induction of these cells might be the underlying mechanism of antidiabetogenic action of WHI-P131 in NOD mice. Our results confirm that JAK3 signaling is a prerequisite for the induction of FoxP3 1 Tregs in vitro. Despite clear in vitro effects, the negative impact of JAK3 inhibition on the FoxP3 1 Tregs was not observed in vivo. Overall, these data provide additional evidence that JAK3 inhibition is a suitable mechanism for the modulation of autoimmune responses. 
JAK3 inhibition induces TGF-b secretion in CD4
1 T cells M Cetkovic-Cvrlje et al 359
